Henry Schein, Inc. (HSIC) Rating Lowered to Hold at Zacks Investment Research
Henry Schein, Inc. (NASDAQ:HSIC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “In the past three months, Henry Schein has consistently outperformed the S&P 500 Market at large with respect to share price movement. Apart from balanced segmental growth across all its operating segments, the company’s share gains in both the U.S. and overseas markets raise optimism. Management is also upbeat about several strategic tie ups made during the reported quarter. We are also positive about Henry Schein’s buyout of Marrodent and SAS which have the potential to capture the bountiful dental market opportunities. On the flip side despite a strong quarterly show last time, the company’s unchanged EPS guidance for 2017 is uninspiring. Meanwhile, Henry Schein’s venture in digital dentistry through Dentsply Sirona deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials.”
HSIC has been the topic of several other research reports. Stifel Nicolaus lifted their price objective on shares of Henry Schein from $174.00 to $178.00 and gave the stock a “hold” rating in a research note on Wednesday, May 10th. Piper Jaffray Companies initiated coverage on shares of Henry Schein in a research note on Monday, June 12th. They issued a “neutral” rating and a $200.00 price target on the stock. Jefferies Group LLC reaffirmed a “hold” rating and issued a $165.00 price target on shares of Henry Schein in a research note on Tuesday, February 28th. Craig Hallum initiated coverage on shares of Henry Schein in a research note on Tuesday, April 11th. They issued a “hold” rating on the stock. Finally, Deutsche Bank AG initiated coverage on shares of Henry Schein in a research note on Wednesday, March 15th. They issued a “hold” rating and a $174.00 price target on the stock. Ten analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $184.08.
Henry Schein (HSIC) traded up 0.10% during mid-day trading on Friday, reaching $184.44. 96,975 shares of the company’s stock traded hands. Henry Schein has a 52-week low of $146.23 and a 52-week high of $186.99. The company has a 50-day moving average of $180.88 and a 200-day moving average of $168.29. The company has a market capitalization of $14.63 billion, a price-to-earnings ratio of 28.03 and a beta of 1.10.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 9th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.65 by $0.11. The company had revenue of $2.92 billion during the quarter, compared to the consensus estimate of $2.83 billion. Henry Schein had a net margin of 4.53% and a return on equity of 19.74%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period last year, the firm earned $1.41 EPS. Equities research analysts expect that Henry Schein will post $7.28 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/06/23/henry-schein-inc-hsic-rating-lowered-to-hold-at-zacks-investment-research.html.
In related news, EVP Gerald A. Benjamin sold 12,578 shares of the business’s stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $175.10, for a total transaction of $2,202,407.80. Following the transaction, the executive vice president now directly owns 44,061 shares in the company, valued at $7,715,081.10. The sale was disclosed in a filing with the SEC, which is available through this link. 1.27% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. increased its position in shares of Henry Schein by 0.8% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 2,576 shares of the company’s stock worth $391,000 after buying an additional 21 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Henry Schein by 8.0% in the fourth quarter. Van ECK Associates Corp now owns 1,077 shares of the company’s stock worth $163,000 after buying an additional 80 shares during the last quarter. Federated Investors Inc. PA increased its position in shares of Henry Schein by 117.8% in the fourth quarter. Federated Investors Inc. PA now owns 4,867 shares of the company’s stock worth $738,000 after buying an additional 2,632 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Henry Schein during the fourth quarter worth $537,000. Finally, Menta Capital LLC purchased a new position in shares of Henry Schein during the fourth quarter worth $297,000. Institutional investors and hedge funds own 90.74% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.